Treatment of premenstrual syndrome by spironolactone.
Spironlactone was given to 28 women in a double blind cross over trial during four menstrual cycles. Hormonal profiles were measured during the first two cycles. Plasma aldosterone was elevated in the premenstrual phase of the cycles but there was no significant difference between symptomatic and asymptomatic groups. The rise in serum progesterone was higher in the symptomatic group during the postovulatory phase. The administration of spironolactone reduced weight and relieved psychological symptoms in more than 80 per cent of the symptomatic group.
D000450:Aldosterone / Q000097:blood; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008598:Menstruation; D011293:Premenstrual Syndrome / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D011374:Progesterone / Q000097:blood; D011897:Random Allocation; D013148:Spironolactone / Q000627:therapeutic use*
D013148:Spironolactone; D000450:Aldosterone; D011374:Progesterone